Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan-Feb;32(1):e23-e24.
doi: 10.1097/DER.0000000000000610.

Hidradenitis Suppurativa Caused by Vedolizumab

Gaetano Licata, Alessio Gambardella, Alina De Rosa, Giulia Calabrese, Roberto Alfano, Giuseppe Argenziano
Case Reports

Hidradenitis Suppurativa Caused by Vedolizumab

Gaetano Licata et al. Dermatitis. 2021 Jan-Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to declare.

References

    1. Pijls PA, Gilissen LP. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti–TNF-alpha therapy–induced dermatological side effects. Dig Liver Dis 2016;48(11):1391–1393.
    1. Fleisher M, Marsal J, Lee SD, et al. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci 2018;63(4):825–833.
    1. Smith MK, Nicholson C, Parks-Miller A, et al. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res 2017;6:1272.
    1. Pouldar D, Elsensohn A, Ortenzio F, et al. Nodular vasculitis in a patient with Crohn's disease on vedolizumab. Am J Dermatopathol 2018;40(3):e36–e37.
    1. Kochar B, Jiang Y, Winn A, et al. The early experience with vedolizumab in the United States. Crohns Colitis 360 2019;1(3):otz027.

MeSH terms

LinkOut - more resources